Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 277
- Registration Number
- NCT01180322
- Locations
- 🇦🇹
Universitätsklinikum Innsbruck, Innsbruck, Austria
🇦🇹Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇦🇹Elisabethinen Krankenhaus Linz, Linz, Austria
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
- Conditions
- Chronic Myeloid LeukemiaAcute Lymphocytic LeukemiaMyeloproliferative DiseaseAcute Myelocytic Leukemia
- Interventions
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01167166
- Locations
- 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: Investigator's Choice
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2013-09-27
- Lead Sponsor
- Clavis Pharma
- Target Recruit Count
- 381
- Registration Number
- NCT01147939
- Locations
- 🇺🇸
Scripps Cancer Center Clinical Research, La Jolla, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸UCLA School of Medicine, Division of Hematology/Oncology, Los Angeles, California, United States
Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Cooperative Study Group A for Hematology
- Target Recruit Count
- 43
- Registration Number
- NCT01146977
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Asanbyeongwon-gil, songpa-gu, Korea, Republic of
A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2010-03-19
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 14
- Registration Number
- NCT01090167
- Locations
- 🇯🇵
Nagoya Daini Red Cross Hospital, Aichi, Japan
🇯🇵National Hospital Organization Nagoya Medical Center, Aichi, Japan
🇯🇵University of Fukui Hospital, Fukui, Japan
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Conventional Care Regimen
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 488
- Registration Number
- NCT01074047
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇦🇺Prince of Wales Hospital, Randwick, New South Wales, Australia
A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2011-01-17
- Lead Sponsor
- Antisoma Research
- Target Recruit Count
- 20
- Registration Number
- NCT01066494
- Locations
- 🇬🇪
Institute of Haematology and Transfusiology, Tbilisi, Georgia
🇬🇪Medulla - Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia
🇬🇪Hema - Haematology and Chemotherapy Clinic, Tbilisi, Georgia
LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloblastic Leukemia
- First Posted Date
- 2009-12-30
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 200
- Registration Number
- NCT01041040
- Locations
- 🇪🇸
Hoapital La Fe, Valencia, Spain
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
- Conditions
- LeukemiaAcute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)Anemia
- Interventions
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Jason Robert Gotlib
- Target Recruit Count
- 2
- Registration Number
- NCT01034592
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 6
- Registration Number
- NCT01027923
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States